{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:29:23Z","timestamp":1789522163995,"version":"build-2803163510"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K09382, 23K08535"],"award-info":[{"award-number":["20K09382, 23K08535"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["SPRING (JPMJSP2119)"],"award-info":[{"award-number":["SPRING (JPMJSP2119)"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["BINDS (24ama121018)"],"award-info":[{"award-number":["BINDS (24ama121018)"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Spinal cord injury results in profound neurological disability driven initially by primary mechanical damage and subsequently by secondary injury processes characterized by progressive neuroinflammation. Intravenous administration of human amniotic mesenchymal stem cells (MSC) has emerged as a promising therapeutic approach; however, the optimal timing of administration and its relationship to dynamic immune responses remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A rat contusion model of spinal cord injury was used to evaluate the effects of intravenous MSC administration at three post-injury time points: days 1, 3, and 7. Functional and histological assessments were performed for each group. Systemic inflammatory responses were evaluated through blood analysis of neutrophil and macrophage counts, systemic inflammation index (SII), and plasma proteomics. Local immune responses were assessed by quantifying infiltrating immune cells within the injured spinal cord.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The most substantial improvement in locomotor function was observed in the day-1 treatment group, followed by the day-7 group, whereas the day-3 group showed minimal benefit. The day-3 group also demonstrated a trend toward greater lesion length and increased macrophage infiltration 28 days after injury. MSC administration reduced SII in the day-1 and day-7 groups but not in the day-3 group, which instead showed an increased systemic inflammatory response. Analysis of spinal cord tissue demonstrated that MSC treatment on day-1 effectively reduced neutrophil infiltration, which peaks at this time point, while day-7 administration reduced macrophage infiltration during its peak phase. In contrast, MSC administration on day-3 failed to attenuate either neutrophil or macrophage accumulation. Plasma proteomic profiling revealed enhanced complement and coagulation pathway activation specifically on day-3.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The therapeutic efficacy of intravenously administered MSC is highly dependent on the timing of intervention. Optimal benefit is achieved when treatment coincides with peak activation of a dominant target immune cell population and avoids the peak of complement and coagulation signaling. These findings support a phase-matched therapeutic strategy to maximize MSC effectiveness following spinal cord injury.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13287-026-05018-0","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:07:33Z","timestamp":1777043253000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Phase-dependent efficacy of intravenous amniotic mesenchymal stem cells in a rat spinal cord injury model"],"prefix":"10.1186","volume":"17","author":[{"given":"Yi","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Kawabori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yo","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumio","family":"Ohtsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Fujimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"issue":"6","key":"5018_CR1","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s41669-024-00517-3","volume":"8","author":"M Diop","year":"2024","unstructured":"Diop M, Epstein D. A systematic review of the impact of spinal cord injury on costs and health-related quality of life. PharmacoEconomics - Open. 2024;8(6):793\u2013808.","journal-title":"PharmacoEconomics - Open"},{"issue":"1","key":"5018_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13018-025-05985-9","volume":"20","author":"W Liu","year":"2025","unstructured":"Liu W, Samuhaer A, Lin K, Li M, Zang C, Liu H, et al. Global epidemiological trends and burden of cervical and subcervical spinal cord injuries, 1990\u20132021: a multidimensional analysis using global burden of disease data. J Orthop Surg Res. 2025;20(1):657.","journal-title":"J Orthop Surg Res"},{"key":"5018_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2016.00098","volume":"10","author":"MA Anwar","year":"2016","unstructured":"Anwar MA, Al Shehabi TS, Eid AH. Inflammogenesis of secondary spinal cord injury. Front Cell Neurosci. 2016;10:98.","journal-title":"Front Cell Neurosci"},{"key":"5018_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1334847","volume":"15","author":"MH Theus","year":"2024","unstructured":"Theus MH. Neuroinflammation and acquired traumatic CNS injury: a mini review. Front Neurol. 2024;15:1334847.","journal-title":"Front Neurol"},{"key":"5018_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20112698","author":"F Cofano","year":"2019","unstructured":"Cofano F, Boido M, Monticelli M, Zenga F, Ducati A, Vercelli A, et al. Mesenchymal stem cells for spinal cord injury: current options, limitations, and future of cell therapy. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20112698.","journal-title":"Int J Mol Sci"},{"key":"5018_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1141601","volume":"14","author":"Y Xia","year":"2023","unstructured":"Xia Y, Zhu J, Yang R, Wang H, Li Y, Fu C. Mesenchymal stem cells in the treatment of spinal cord injury: mechanisms, current advances and future challenges. Front Immunol. 2023;14:1141601.","journal-title":"Front Immunol"},{"key":"5018_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21113994","author":"K Yamazaki","year":"2020","unstructured":"Yamazaki K, Kawabori M, Seki T, Houkin K. Clinical trials of stem cell treatment for spinal cord injury. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21113994.","journal-title":"Int J Mol Sci"},{"key":"5018_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00238","volume":"10","author":"M Abbasi-Kangevari","year":"2019","unstructured":"Abbasi-Kangevari M, Ghamari S-H, Safaeinejad F, Bahrami S, Niknejad H. Potential therapeutic features of human amniotic mesenchymal stem cells in multiple sclerosis: immunomodulation, inflammation suppression, angiogenesis promotion, oxidative stress inhibition, neurogenesis induction, MMPs regulation, and remyelination stimulation. Front Immunol. 2019;10:238.","journal-title":"Front Immunol"},{"issue":"7","key":"5018_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0270606","volume":"17","author":"S Takamiya","year":"2022","unstructured":"Takamiya S, Kawabori M, Yamazaki K, Yamaguchi S, Tanimori A, Yamamoto K, et al. Intravenous transplantation of amnion-derived mesenchymal stem cells promotes functional recovery and alleviates intestinal dysfunction after spinal cord injury. PLoS One. 2022;17(7):e0270606.","journal-title":"PLoS One"},{"issue":"5","key":"5018_CR10","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1089\/scd.2008.0253","volume":"18","author":"UM Fischer","year":"2009","unstructured":"Fischer UM, Harting MT, Jimenez F, Monzon-Posadas WO, Xue H, Savitz SI, Laine GA, Cox CS. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev. 2009;18(5):683\u201392.","journal-title":"Stem Cells Dev"},{"issue":"7","key":"5018_CR11","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/sctm.18-0192","volume":"8","author":"R Vawda","year":"2019","unstructured":"Vawda R, Badner A, Hong J, Mikhail M, Lakhani A, Dragas R, et al. Early intravenous infusion of mesenchymal stromal cells exerts a tissue source age-dependent beneficial effect on neurovascular integrity and neurobehavioral recovery after traumatic cervical spinal cord injury. Stem Cells Transl Med. 2019;8(7):639\u201349.","journal-title":"Stem Cells Transl Med"},{"issue":"1","key":"5018_CR12","doi-asserted-by":"publisher","first-page":"e0190358","DOI":"10.1371\/journal.pone.0190358","volume":"13","author":"KL Lankford","year":"2018","unstructured":"Lankford KL, Arroyo EJ, Nazimek K, Bryniarski K, Askenase PW, Kocsis JD. Intravenously delivered mesenchymal stem cell-derived exosomes target M2-type macrophages in the injured spinal cord. PLoS One. 2018;13(1):e0190358.","journal-title":"PLoS One"},{"issue":"4","key":"5018_CR13","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/stem.2779","volume":"36","author":"SFH de Witte","year":"2018","unstructured":"de Witte SFH, Luk F, Sierra Parraga JM, Gargesha M, Merino A, Korevaar SS, et al. Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytic cells. Stem Cells. 2018;36(4):602\u201315.","journal-title":"Stem Cells"},{"key":"5018_CR14","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.brainres.2010.05.011","volume":"1343","author":"M Osaka","year":"2010","unstructured":"Osaka M, Honmou O, Murakami T, Nonaka T, Houkin K, Hamada H, Kocsis JD. Intravenous administration of mesenchymal stem cells derived from bone marrow after contusive spinal cord injury improves functional outcome. Brain Res. 2010;1343:226\u201335.","journal-title":"Brain Res"},{"key":"5018_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/biology10030230","author":"LDV Johnson","year":"2021","unstructured":"Johnson LDV, Pickard MR, Johnson WEB. The comparative effects of mesenchymal stem cell transplantation therapy for spinal cord injury in humans and animal models: a systematic review and meta-analysis. Biology. 2021. https:\/\/doi.org\/10.3390\/biology10030230.","journal-title":"Biology"},{"issue":"15","key":"5018_CR16","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1089\/neu.2019.6905","volume":"37","author":"K Yamazaki","year":"2020","unstructured":"Yamazaki K, Kawabori M, Seki T, Takamiya S, Tateno T, Konno K, et al. FTY720 attenuates neuropathic pain after spinal cord injury by decreasing systemic and local inflammation in a rat spinal cord compression model. J Neurotrauma. 2020;37(15):1720\u20138.","journal-title":"J Neurotrauma"},{"key":"5018_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25042406","author":"Y Morishima","year":"2024","unstructured":"Morishima Y, Kawabori M, Yamazaki K, Takamiya S, Yamaguchi S, Nakahara Y, et al. Intravenous administration of mesenchymal stem cell-derived exosome alleviates spinal cord injury by regulating neutrophil extracellular trap formation through exosomal miR-125a-3p. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25042406.","journal-title":"Int J Mol Sci"},{"key":"5018_CR18","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9964877","volume":"2021","author":"K Yamazaki","year":"2021","unstructured":"Yamazaki K, Kawabori M, Seki T, Takamiya S, Konno K, Watanabe M, et al. Mesenchymal stem cell sheet promotes functional recovery and palliates neuropathic pain in a subacute spinal cord injury model. Stem Cells Int. 2021;2021:9964877.","journal-title":"Stem Cells Int"},{"key":"5018_CR19","doi-asserted-by":"publisher","first-page":"115143","DOI":"10.1016\/j.expneurol.2025.115143","volume":"386","author":"S Gotoh","year":"2025","unstructured":"Gotoh S, Kawabori M, Yamaguchi S, Nakahara Y, Yoshie E, Konno K, Mizuno Y, Fujioka Y, Ohba Y. Kuge Y and others. Intranasal administration of stem cell-derived exosome alleviates cognitive impairment against subarachnoid hemorrhage. Exp Neurol. 2025;386:115143.","journal-title":"Exp Neurol"},{"key":"5018_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16040446","author":"T Ikeda","year":"2024","unstructured":"Ikeda T, Kawabori M, Zheng Y, Yamaguchi S, Gotoh S, Nakahara Y, et al. Intranasal administration of mesenchymal stem cell-derived exosome alleviates hypoxic-ischemic brain injury. Pharmaceutics. 2024. https:\/\/doi.org\/10.3390\/pharmaceutics16040446.","journal-title":"Pharmaceutics"},{"issue":"3","key":"5018_CR21","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/j.1440-1789.2011.01260.x","volume":"32","author":"M Kawabori","year":"2011","unstructured":"Kawabori M, Kuroda S, Sugiyama T, Ito M, Shichinohe H, Houkin K, et al. Intracerebral, but not intravenous, transplantation of bone marrow stromal cells enhances functional recovery in rat cerebral infarct: an optical imaging study. Neuropathology. 2011;32(3):217\u201326.","journal-title":"Neuropathology"},{"issue":"2","key":"5018_CR22","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/j.1440-1789.2012.01335.x","volume":"33","author":"M Kawabori","year":"2012","unstructured":"Kawabori M, Kuroda S, Ito M, Shichinohe H, Houkin K, Kuge Y, Tamaki N. Timing and cell dose determine therapeutic effects of bone marrow stromal cell transplantation in rat model of cerebral infarct. Neuropathology: Official J Japanese Soc Neuropathology. 2012;33(2):140\u20138.","journal-title":"Neuropathology: Official J Japanese Soc Neuropathology"},{"key":"5018_CR23","doi-asserted-by":"publisher","DOI":"10.1089\/neu.1995.12.1","author":"DM Basso","year":"1995","unstructured":"Basso DM, Beattie MS, Bresnahan JC. A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma. 1995. https:\/\/doi.org\/10.1089\/neu.1995.12.1.","journal-title":"J Neurotrauma"},{"issue":"4","key":"5018_CR24","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1097\/00005072-195312040-00008","volume":"12","author":"H Kluver","year":"1953","unstructured":"Kluver H, Barrera E. A method for the combined staining of cells and fibers in the nervous system. J Neuropathol Exp Neurol. 1953;12(4):400\u20133.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"8","key":"5018_CR25","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1523\/JNEUROSCI.2620-14.2015","volume":"35","author":"M Kawabori","year":"2015","unstructured":"Kawabori M, Kacimi R, Kauppinen T, Calosing C, Kim JY, Hsieh CL, Nakamura MC, Yenari MA. Triggering receptor expressed on myeloid cells 2 (TREM2) deficiency attenuates phagocytic activities of microglia and exacerbates ischemic damage in experimental stroke. J Neurosci. 2015;35(8):3384\u201396.","journal-title":"J Neurosci"},{"issue":"2","key":"5018_CR26","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/j.1440-1789.2012.01335.x","volume":"33","author":"M Kawabori","year":"2013","unstructured":"Kawabori M, Kuroda S, Ito M, Shichinohe H, Houkin K, Kuge Y, Tamaki N. Timing and cell dose determine therapeutic effects of bone marrow stromal cell transplantation in rat model of cerebral infarct. Neuropathology. 2013;33(2):140\u20138.","journal-title":"Neuropathology"},{"issue":"3","key":"5018_CR27","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/j.1440-1789.2011.01260.x","volume":"32","author":"M Kawabori","year":"2012","unstructured":"Kawabori M, Kuroda S, Sugiyama T, Ito M, Shichinohe H, Houkin K, et al. Intracerebral, but not intravenous, transplantation of bone marrow stromal cells enhances functional recovery in rat cerebral infarct: an optical imaging study. Neuropathology. 2012;32(3):217\u201326.","journal-title":"Neuropathology"},{"issue":"23","key":"5018_CR28","doi-asserted-by":"publisher","first-page":"6212","DOI":"10.1158\/1078-0432.CCR-14-0442","volume":"20","author":"B Hu","year":"2014","unstructured":"Hu B, Yang X-R, Xu Y, Sun Y-F, Sun C, Guo W, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20(23):6212\u201322.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"5018_CR29","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1021\/acs.jproteome.4c00149","volume":"23","author":"K Gu","year":"2024","unstructured":"Gu K, Kumabe H, Yamamoto T, Tashiro N, Masuda T, Ito S, et al. Improving proteomic identification using narrow isolation windows with Zeno SWATH data-independent acquisition. J Proteome Res. 2024;23(8):3484\u201395.","journal-title":"J Proteome Res"},{"issue":"6","key":"5018_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.104810","volume":"299","author":"K Etoh","year":"2023","unstructured":"Etoh K, Nakao M. A web-based integrative transcriptome analysis, RNAseqChef, uncovers the cell\/tissue type-dependent action of sulforaphane. J Biol Chem. 2023;299(6):104810.","journal-title":"J Biol Chem"},{"issue":"D1","key":"5018_CR31","doi-asserted-by":"publisher","first-page":"D605","DOI":"10.1093\/nar\/gkaa1074","volume":"49","author":"D Szklarczyk","year":"2021","unstructured":"Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, Doncheva NT, Legeay M, Fang T. Bork P and others. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene\/measurement sets. Nucleic Acids Res. 2021;49(D1):D605\u201312.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"5018_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-020-1726-7","volume":"17","author":"W Liu","year":"2020","unstructured":"Liu W, Rong Y, Wang J, Zhou Z, Ge X, Ji C, et al. Exosome-shuttled miR-216a-5p from hypoxic preconditioned mesenchymal stem cells repair traumatic spinal cord injury by shifting microglial M1\/M2 polarization. J Neuroinflammation. 2020;17(1):47.","journal-title":"J Neuroinflammation"},{"key":"5018_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2025.1532219","volume":"19","author":"R Wang","year":"2025","unstructured":"Wang R, Wang Y, Yan F, Sun J, Zhang T. Assessment of mesenchymal stem cells for the treatment of spinal cord injury: a systematic review and network meta-analysis. Front Cell Neurosci. 2025;19:1532219.","journal-title":"Front Cell Neurosci"},{"issue":"6","key":"5018_CR34","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1002\/stem.2006","volume":"33","author":"S Watanabe","year":"2015","unstructured":"Watanabe S, Uchida K, Nakajima H, Matsuo H, Sugita D, Yoshida A, Honjoh K, Johnson WEB, Baba H. Early transplantation of mesenchymal stem cells after spinal cord injury relieves pain hypersensitivity through suppression of pain-related signaling cascades and reduced inflammatory cell recruitment. Stem Cells. 2015;33(6):1902\u201314.","journal-title":"Stem Cells"},{"issue":"1","key":"5018_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-022-03103-8","volume":"13","author":"Y Lu","year":"2022","unstructured":"Lu Y, Zhang W, Tian Z, Liang Q, Liu C, Wu Y, et al. The optimal transplantation strategy of umbilical cord mesenchymal stem cells in spinal cord injury: a systematic review and network meta-analysis based on animal studies. Stem Cell Res Ther. 2022;13(1):441.","journal-title":"Stem Cell Res Ther"},{"key":"5018_CR36","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.neuroscience.2016.08.037","volume":"335","author":"T Morita","year":"2016","unstructured":"Morita T, Sasaki M, Kataoka-Sasaki Y, Nakazaki M, Nagahama H, Oka S, et al. Intravenous infusion of mesenchymal stem cells promotes functional recovery in a model of chronic spinal cord injury. Neuroscience. 2016;335:221\u201331.","journal-title":"Neuroscience"},{"key":"5018_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2021.106565","volume":"203","author":"O Honmou","year":"2021","unstructured":"Honmou O, Yamashita T, Morita T, Oshigiri T, Hirota R, Iyama S, et al. Intravenous infusion of auto serum-expanded autologous mesenchymal stem cells in spinal cord injury patients: 13 case series. Clin Neurol Neurosurg. 2021;203:106565.","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"5018_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-020-01855-9","volume":"11","author":"X Wu","year":"2020","unstructured":"Wu X, Jiang J, Gu Z, Zhang J, Chen Y, Liu X. Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress. Stem Cell Res Ther. 2020;11(1):345.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"5018_CR39","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nm.1905","volume":"15","author":"K N\u00e9meth","year":"2008","unstructured":"N\u00e9meth K, Leelahavanichkul A, Yuen PST, Mayer B, Parmelee A, Doi K, Robey PG, Leelahavanichkul K, Koller BH. Brown JM and others. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med. 2008;15(1):42\u20139.","journal-title":"Nat Med"},{"issue":"1","key":"5018_CR40","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.stem.2009.05.003","volume":"5","author":"RH Lee","year":"2009","unstructured":"Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, Semprun-Prieto L, Delafontaine P, Prockop DJ. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell. 2009;5(1):54\u201363.","journal-title":"Cell Stem Cell"},{"issue":"5","key":"5018_CR41","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/s12276-023-00986-2","volume":"55","author":"L Chen","year":"2023","unstructured":"Chen L, Liu Y, Wang Z, Zhang L, Xu Y, Li Y, Zhang L, Wang G, Yang S, Xue G. Mesenchymal stem cell-derived extracellular vesicles protect against abdominal aortic aneurysm formation by inhibiting NET-induced ferroptosis. Exp Mol Med. 2023;55(5):939\u201351.","journal-title":"Exp Mol Med"},{"issue":"1","key":"5018_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-021-02337-2","volume":"18","author":"DJ Hellenbrand","year":"2021","unstructured":"Hellenbrand DJ, Quinn CM, Piper ZJ, Morehouse CN, Fixel JA, Hanna AS. Inflammation after spinal cord injury: a review of the critical timeline of signaling cues and cellular infiltration. J Neuroinflammation. 2021;18(1):284.","journal-title":"J Neuroinflammation"},{"issue":"1","key":"5018_CR43","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12712","volume":"53","author":"W Jiang","year":"2019","unstructured":"Jiang W, Xu J. Immune modulation by mesenchymal stem cells. Cell Prolif. 2019;53(1):e12712.","journal-title":"Cell Prolif"},{"key":"5018_CR44","doi-asserted-by":"crossref","unstructured":"Est\u00faa-Acosta GA, Buentello-Volante B, Maga\u00f1a-Guerrero FS, Flores JE-A, Vivanco-Rojas O, Castro-Salas I, Zarco-\u00c1vila K, Garc\u00eda-Mej\u00eda MA, Garfias Y. Human Amniotic Membrane Mesenchymal Stem Cell-Synthesized PGE2 Exerts an Immunomodulatory Effect on Neutrophil Extracellular Trap in a PAD-4-Dependent Pathway through EP2 and EP4. Cells 2022;11(18).","DOI":"10.3390\/cells11182831"},{"issue":"11","key":"5018_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12137","volume":"10","author":"M Nakazaki","year":"2021","unstructured":"Nakazaki M, Morita T, Lankford KL, Askenase PW, Kocsis JD. Small extracellular vesicles released by infused mesenchymal stromal cells target M2 macrophages and promote TGF-\u03b2 upregulation, microvascular stabilization and functional recovery in a rodent model of severe spinal cord injury. J Extracell Vesicles. 2021;10(11):e12137.","journal-title":"J Extracell Vesicles"},{"key":"5018_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.624746","volume":"12","author":"N Luque-Campos","year":"2021","unstructured":"Luque-Campos N, Bustamante-Barrientos FA, Pradenas C, Garc\u00eda C, Araya MJ, Bohaud C, et al. The macrophage response is driven by mesenchymal stem cell-mediated metabolic reprogramming. Frontiers In Immunology. 2021;12:624746.","journal-title":"Frontiers In Immunology"},{"key":"5018_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/medicines8040016","author":"G Savioli","year":"2021","unstructured":"Savioli G, Ceresa IF, Caneva L, Gerosa S, Ricevuti G. Trauma-induced coagulopathy: overview of an emerging medical problem from pathophysiology to outcomes. Medicines. 2021. https:\/\/doi.org\/10.3390\/medicines8040016.","journal-title":"Medicines"},{"issue":"1","key":"5018_CR48","doi-asserted-by":"publisher","first-page":"106","DOI":"10.7150\/thno.16911","volume":"7","author":"L Liao","year":"2017","unstructured":"Liao L, Shi B, Chang H, Su X, Zhang L, Bi C, et al. Heparin improves BMSC cell therapy: anticoagulant treatment by heparin improves the safety and therapeutic effect of bone marrow-derived mesenchymal stem cell cytotherapy. Theranostics. 2017;7(1):106\u201316.","journal-title":"Theranostics"},{"issue":"7","key":"5018_CR49","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1002\/stem.1111","volume":"30","author":"G Moll","year":"2012","unstructured":"Moll G, Rasmusson-Duprez I, von Bahr L, Connolly-Andersen AM, Elgue G, Funke L, et al. Are therapeutic human mesenchymal stromal cells compatible with human blood? Stem Cells. 2012;30(7):1565\u201374.","journal-title":"Stem Cells"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-026-05018-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-05018-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-05018-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:03:55Z","timestamp":1781136235000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13287-026-05018-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5018"],"URL":"https:\/\/doi.org\/10.1186\/s13287-026-05018-0","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal protocols were approved by the Animal Studies Ethics Committee of the Hokkaido University Graduate School of Medicine. Experimental title: basic experiment of stem cell treatment for brain disease. Approval number: 21\u20130123. Date of approval: 2022\/11\/14. All experimental procedures were conducted following the Institutional Guidelines for Animal Experimentation and the Guidelines for Proper Conduct of Animal Experiments by the Science Council of Japan. All animals were housed in standard polypropylene cages (typically 2\u20133 rats per cage) under specific pathogen-free (SPF) conditions. The animal facility was maintained at a temperature of 22\u2009\u00b1\u20092\u00a0\u00b0C, with relative humidity of 50\u201360% and a 12-hour light\/dark cycle. Rats had ad libitum access to autoclaved food and water. Animals were monitored daily for health and welfare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agreed to submit the manuscript, read and approved the final draft and take full responsibility of its content, including the accuracy of the data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"208"}}